海外の治験の状況「1」での検索結果
1245件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- A MULTICENTER, MULTINATIONAL, PROSPECTIVE, INTERVENTIONAL, SINGLE-ARM, PHASE IV STUDY EVALUATING THE CLINICAL EFFICACY AND SAFETY OF 26 WEEKS OF TREATMENT WITH INSULIN GLARGINE 300 U/ML (GLA-300) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNCONTROLLED ON BASAL INSULIN
- -E10 Insulin-dependent diabetes mellitus br>Insulin-dependent diabetes mellitus;E10 ;Insulin-dependent diabetes mellitus
- Arabia Saudi, Argentina, China, Colombia, Egypt, India, Indonesia, Lebano, Malasya, Peru, Philippines, South Africa, Thailand, Tunisia, Turkey
- 2019-06-26
Not Recruiting
- Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.
- Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day as single agent first line treatment.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Belgium, Brazil, Bulgaria, Canada, Colombia, Germany, Greece, Italy, Mexico, Slovakia, Spain, Switzerland, United Kingdom
- 2015-04-09
Not recruiting
- Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
- Neurofibromatosis 1;Cutaneous Neurofibroma;Neurofibromatosis 1;Cutaneous Neurofibroma;Neurofibromatosis 1;Cutaneous Neurofibroma;Neurofibromatosis 1;Cutaneous Neurofibroma
- Brazil
- 2017-03-08
Authorised
- A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 17.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 16.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Not recruiting
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
- Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1;Diabetes;Diabetes Mellitus, Type 1
- Belgium, Brazil, Canada, Croatia, Czech Republic, India, Israel, Macedonia, The Former Yugoslav Republic of, Poland, Russian Federation, Serbia, Slovenia, South Africa, Spain, United States
- 2013-04-16
Not Recruiting
- Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.
- Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Belgium, Brazil, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Mexico, Slovakia, Spain, United Kingdom
- 2015-08-06
Recruiting
- Effect of vaginal contraction exercise in bladder control in women with multiple sclerosis and neurological disease caused by the virus HTLV1
- Multiple sclerosis and Tropical spastic paraparesis in the carrier of T-lymphotropic virus type 1 infection [HTLV-1] C10.114.375.500 G35 C02.782.815.200.470.710 G95.8 Z22.6;G00-G99;C10.114.375.500;C02.782.815.200.470.710
- Brazil
- 2017-07-19
Recruiting
- Evaluation of the effects of protein supplementation on postmeal plasma glucose in adults with type 1 diabetes mellitus
- Type 1 Diabetes Mellitus br>C18.452.394.750.124;E00-E90;C18.452.394.750.124
- Brazil
- 2018-05-04
Not recruiting
- HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons
- HIV Infections;Herpes Simplex;Sexually Transmitted Diseases
- Peru
- 2007-04-23